

MINUTES
INSTITUTIONAL BIOSAFETY COMMITTEE
DATE: June 12, 2026

Attendance: Total Attending: 11

Voting Members Present: 10

Called to Order: 10:02 a.m.

Name	Expertise	Present
Linda Cassidy, MS	Non-Voting Member	X
Sue Gotta, MS	rDNA; Select Agents	X
Gerald Grunwald, PhD	rDNA; Biochemistry; Cellular & Developmental Biology	X
Douglas C. Hooper, PhD	rDNA; Immunology; Gene Transfer	X
Botond Igyarto, PhD	Microbiology	X
Loretta Kelly, Esq.	Non-affiliate Community Member	X
Kathleen “Kitty” Kono	Non-Affiliate Community Member	X
Phil LaTourette, DVM	Laboratory Animal Sciences	
Sara Meyer, PhD	Cancer Biology	X
Fabienne Paumet, PhD	Cellular Biology & Biochemistry	X
Drake Stierman	Safety Officer	X
Megan Watson, MS	Lab Specialist	X

MINUTES REVIEWED:

Minutes of the May 8, 2026 meeting were presented for review.

Motion to Approve: Douglas C. Hooper

Seconded: Kitty Kono

Total = #10; For-#9, Opposed-#0, Abstained-#1

NEW PROTOCOLS:

1. Principal Investigator M.R.

IBC Control# 26-03-1020

Summary:

- This protocol involves looking at the Env viral surface protein of HIV-1.
- This is an in vitro study.
- The principal risks identified were:
 - HIV
 - E. coli plasmid vectors
 - Human cell lines
- Containment has been set to BSL-2.

Committee Review:

- This protocol was reviewed under NIH Category D.
- The risks were adequately identified by the Principal Investigator and appropriate mitigation was described in the protocol.
- Clarifications were requested.
- A motion was made and seconded to provisionally approve this protocol. The motion was unanimously approved.

2. Principal Investigator P.S.

IBC Control# 26-05-1030

Summary:

- This protocol is studying protein N-myristoylation and N-myristoyltransferases enzymes.
- This is an in vitro study.
- The principal risks identified were:
 - Human cell lines
 - shRNA
- Containment has been set to BSL-2.

Committee Review:

- This protocol was reviewed under NIH Category E.
- The risks were adequately identified by the Principal Investigator and appropriate mitigation was described in the protocol.
- Clarifications were requested.
- A motion was made and seconded to provisionally approve this protocol. The motion was unanimously approved.

ADMINISTRATIVELY APPROVED ITEMS:

The KSI database indicates the following items have been given administrative approval since our last meeting:

June 12, 2026

Protocol #	PI - Initials	Form type	Comments
24-10-989	PS	Amendment	Updated personnel and clinical protocols, clinical trial
22-10-586	JH	New	Submittal of previously approved work
22-08-537	TS	New	Work with human hematopoietic stem cells
22-09-556	DM	New	Submittal of previously approved work
23-05-681-1	AF	Continuing Review	Active - no updates, 3 yr review
25-04-943	PC	Continuing Review	Active - no updates
24-04-831	JN	Continuing Review	Active - updated personnel & protocol summary
24-04-837	BE	Continuing Review	Active - updated research location
23-08-716	TC	Continuing Review	Active - no updates
22-09-572	BC	New	Submittal of previously approved work
25-04-945	MS	Continuing Review	Not started - no updates, clinical trial
21-08-419	CS	New	Submittal of previously approved work
24-01-781	AA	Continuing Review	Active - updated personnel
21-03-360-1	AJ	Amendment	Updated personnel

OTHER BUSINESS:

- The committee was asked to review the IBC Policy & Procedure Manual which will be moved to a newly created IBC Teams folder.
- The committee was asked to add commonly used vectors to the list in the IBC Teams folder. This will be used to populate the dropdown menu in our database. The committee agreed that specific vectors (e.g., Adeno 5) should be added to the database.
- The committee thanked Douglas C. Hooper for his years of service on the IBC. Craig is retiring from Jefferson.
- The committee continued to discuss the use of central IBCs for industry sponsored clinical trials.

Meeting Adjourned: 10:58 a.m.

Respectfully submitted for the IBC,

/s/Gerald Grunwald, PhD
Chair, Institutional Biosafety Committee

GG/lc